This Differentiation Block Will Not Stand, Man: Ivosidenib for MDS

Overview

Journal Blood Adv

Specialty Hematology

Date 2024 Aug 13

PMID 39136969

Authors

Ryan J Beechinor

Brian A Jonas

Affiliations

Soon will be listed here.

References

DiNardo C, Roboz G, Watts J, Madanat Y, Prince G, Baratam P . Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome. Blood Adv. 2024; 8(15):4209-4220. PMC: 11372395. DOI: 10.1182/bloodadvances.2023012302. View

Pratz K, Jonas B, Pullarkat V, Thirman M, Garcia J, Dohner H . Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024; 99(4):615-624. DOI: 10.1002/ajh.27246. View

Bewersdorf J, Zeidan A . Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?. Best Pract Res Clin Haematol. 2021; 34(1):101245. DOI: 10.1016/j.beha.2021.101245. View

Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G . Ivosidenib and Azacitidine in -Mutated Acute Myeloid Leukemia. N Engl J Med. 2022; 386(16):1519-1531. DOI: 10.1056/NEJMoa2117344. View

Balducci L . Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006; 106(10):2087-94. DOI: 10.1002/cncr.21860. View

Platzbecker U, Kubasch A, Homer-Bouthiette C, Prebet T . Current challenges and unmet medical needs in myelodysplastic syndromes. Leukemia. 2021; 35(8):2182-2198. PMC: 8324480. DOI: 10.1038/s41375-021-01265-7. View

Pollyea D, DiNardo C, Arellano M, Pigneux A, Fiedler W, Konopleva M . Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Clin Cancer Res. 2022; 28(13):2753-2761. PMC: 9365354. DOI: 10.1158/1078-0432.CCR-21-3467. View

Wang N, Wang F, Shan N, Sui X, Xu H . IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes. Acta Haematol. 2017; 138(3):143-151. DOI: 10.1159/000479546. View

Patnaik M, Hanson C, Hodnefield J, Lasho T, Finke C, Knudson R . Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia. 2011; 26(1):101-5. DOI: 10.1038/leu.2011.298. View

10.

Dinh A, Savoy J, Kontoyiannis D, Takahashi K, Issa G, Kantarjian H . Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2024; 130(11):1964-1971. DOI: 10.1002/cncr.35251. View

11.

Thol F, Weissinger E, Krauter J, Wagner K, Damm F, Wichmann M . IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010; 95(10):1668-74. PMC: 2948091. DOI: 10.3324/haematol.2010.025494. View

12.

Saygin C, Carraway H . Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021; 48:100791. DOI: 10.1016/j.blre.2020.100791. View